Depocyt
PreclinicalSmall molecule
Depocyt is one of 68 small molecule programs targeting Acute Lymphoblastic Leukemia. It is currently in Preclinical.
2
Indications
3
Total Trials
0
Active Trials
67
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
408 competitors in Acute Lymphoblastic Leukemia
#DrugCompanyPhaseTrials
1Rituxan
RochePhase 3
Oncovin
EEastern Cooperative Oncology Group
Phase 3
Cerubidine
EEastern Cooperative Oncology Group
Phase 3
Wellcovorin
EEastern Cooperative Oncology Group
Phase 3
Medrol
PfizerPhase 3
Neupogen
EEastern Cooperative Oncology Group
Phase 3
Arranon
NovartisPhase 3
Tepadina
Alnylam PharmaceuticalsPhase 3
Clolar
GGenzyme, a Sanofi Company
Phase 3
Prograf
VVeloxis Pharmaceuticals
Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Depocyt. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Preclinical[1]
- Company
- MM.D. Anderson Cancer Center